echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Fuhong Henlius PD-1 is reported to be listed for priority review!

    Fuhong Henlius PD-1 is reported to be listed for priority review!

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 21, the official website of CDE revealed that the listing application of Fuhong Henlius "slulimumab injection" is planned to be included in the priority review and approval (acceptance number has not yet been announced), for use in cases that have failed, unresectable, or transferred after standard treatment High degree of microsatellite instability-high (MSI-H) solid tumors.


    According to the clinical progress disclosed by Fuhong Henlius before, struzumab should be its PD-1 monoclonal antibody HLX10.


    On March 28 this year, Henlius announced its PD-1 monoclonal antibody HLX10 for unresectable or metastatic highly microsatellite instability (MSI-H) or mismatch repair defect (dMMR) that has failed standard treatments.


    The study is a single-arm, open, multi-center, phase 2 clinical trial designed to evaluate the efficacy, safety and tolerability of HLX10 in patients with unresectable or metastatic MSI-H solid tumors who have failed standard treatments Yes, clinical research results show that HLX10 has good efficacy and safety in this type of indication.


    HLX10 is an innovative anti-PD-1 monoclonal antibody independently developed by Henlius.


    HLX10 clinical trial launch (Insight)

    From the Insight database (http://db.


    The domestic PD-1 competition has now become fierce.


    Domestic PD-1 competition (only the first 20 companies are intercepted)



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.